奥希替尼治疗非小细胞肺癌患者的耐药机制研究进展(4)
[7] Minari R，Bordi P，La Monica S，et al. Concurrent Acquired BRAF V600E Mutation and MET Amplification as Resistance Mechanism of First-Line Osimertinib Treatment in a Patient with EGFR-Mutated NSCLC [J]. J Thorac Oncol，2018，13：e89-e91.[8] Oxnard GR，Hu Y，Mileham KF，et al. Assessment of Resistance Mechanisms and Clinical Implications in Patients with EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib [J]. JAMA Oncol ......
您现在查看是摘要页，全文长 2629 字符。